Prostate Cancer Rewired: Existing Drugs Exploit Receptor-Linked Weakness

Scientists uncover how neuroendocrine prostate cancer develops, offering promising targets for future therapies.

A new line of research has revealed potential therapeutic paths for addressing one of the deadliest forms of prostate cancer.

The team at McGill University’s Rosalind and Morris Goodman Cancer Institute (GCI) has determined a mechanism underlying neuroendocrine prostate cancer, a rare and extremely aggressive form for which effective treatments do not yet exist.().

TOP INSIGHT

Did You Know?
#Pancreatic_tumors can grow less than 2 cm and still spread early, because the pancreas has dense, fibrous tissue that blocks drugs, #immune_cells, and even imaging clarity, making treatment extremely difficult even when tumors are small. #pancreaticcancer #cancerscience #cancertreatment #medindia

ERRγ Loss Accelerates Tumour Aggression and Therapy Resistance Findings published in Genes & Development show that prostate tumours in mice became more aggressive when the protein ERRγ was lost, while restoring its production in human cancer cells reversed this effect.

Prostate cancer is the most commonly diagnosed cancer among men in Canada. Tumours that stop responding to hormone therapy evolve into neuroendocrine prostate cancer in about 15 per cent of patients, according to past research. After this shift, life expectancy typically falls below 18 months.

“Therapy resistance remains one of the biggest challenges in cancer treatment, and prostate cancer is no exception,” said lead author Vincent Giguère, Professor in McGill’s Department of Biochemistry and GCI researcher. “Our findings highlight ERRγ as a promising new therapeutic target.”

Existing Gene-Targeting Drugs Show Promise When ERRγ Is Lost The researchers used advanced genetic and metabolic analysis to understand how losing ERRγ drives tumour growth. Their investigation revealed that two genes linked to cancer become overactive when ERRγ is missing.

As drugs that block these genes already exist for other cancers, the team tested two of them in mouse and human prostate cancer cells. When combined, the two drugs slowed the cancerous growth far more effectively than either drug alone.

Benign Prostatic Hyperplasia Assessment | Prostate Self Assessment Calculator
Benign Prostatic Hyperplasia Assessment or Prostate Self Assessment Calculator assesses the symptoms of enlarged prostate gland and gives an early warning for benign prostatic hyperplasia.

“These findings have major clinical implications,” said Giguère. “By targeting the genes that take over when ERRγ activity is low or lost, we open the door to new treatment strategies for patients who currently have few options.”

Understanding why ERRγ function becomes impaired in the first place is still being investigated, he added.

Quiz on Prostate Cancer
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it’s too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as ...

ERRγ Functions as a Brake on Tumour Progression ERRγ, previously known for its role in energy metabolism, appears to act as a brake that prevents prostate cancer from advancing.

Preclinical findings led by first author Ting Li, a post-doctoral fellow in Giguère’s lab, have revealed that neuroendocrine prostate cancers have much lower levels of ERRγ than other types of prostate tumours. Removing the protein in mice sped up tumour progression, while reactivating the protein in human prostate cancer cells reversed the process, confirming its protective effect.

Reference:

New therapeutic strategies show promise against a hard-to-treat prostate cancer - (https://ecancer.org/en/news/27301-new-therapeutic-strategies-show-promise-against-a-hard-to-treat-prostate-cancer)

Source-McGill University